Investigate / reported ownership
RYTM
Rhythm Pharmaceuticals Inc
2 tracked reported owners · snapshot updated 2026-10-04. Delayed disclosures, not live holdings or an investment recommendation.
Who reports owning RYTM?
Select a manager to inspect their portfolio. Reports may cover different quarters; portfolio weights describe disclosed long 13F holdings, not total economic exposure.
| #↑ | Manager | % Port. | History | Value | Shares |
|---|---|---|---|---|---|
| 1 | Joel Greenblatt | 0.1% | 26q | $140M | 1,263,652 |
| 2 | Stanley Druckenmiller | 0.5% | — 1q | $23M | 203,618 |
Go beyond ownership.
A reviewed company brief is not available yet. You can inspect reported owners above and their filings below, then save this company for further research.
We have not generated a business case or inferred manager motives from these holdings.
Filing dates and original SEC sources
Your research workspace / RYTM
Ask better questions. Keep the evidence.
Explore the available sources for RHYTHM PHARMACEUTICALS INC, then keep what deserves another look.
01 Investor activity
Reported evidence
Who reports owning it?
2 tracked reported owners in the snapshot generated 2026-10-04. Reports can cover different quarters. These are delayed disclosures, not live positions, total economic exposure, endorsements or reasons for investing.
02 Business evidence
No reviewed company brief is available. Business results, case and risks have not been established here.
03 Questions to investigate
Open saved takeaways →Reported position changes
Net disclosed share changes—not individual trades or execution dates. NEW has no prior-position percentage comparison; EXIT weight refers to the previous report.
| Manager | Move | % Port. | Δ Shares | Value | Filed |
|---|---|---|---|---|---|
| Stanley Druckenmiller | NEW | 0.5% | New position | $23M | Aug 14, 2026 |
Keep your next step small.
Save the company and inspect its evidence. Recording a private view is optional and requires a separate, explicit save.
Record my own view →Optional email follow
Latticework Follow
Follow RYTM
Email me only when a reviewed weekly edition contains a material new decision about RYTM: a new position, exit, or a large share-count change that also clears the size threshold. There may be quiet weeks.
Confirm by email. Manage or stop follows in one click. See our privacy notice.
Long US 13F disclosures omit shorts and can be amended. CUSIP 76243J105. No current price, valuation or manager motive is inferred.